Economy & Policy

Florida Regulators Slap 12 PBMs With $12.6 Million in Fines

Florida's insurance regulator has fined 12 pharmacy benefit managers more than $12 million after market conduct exams flagged pricing and contract violations, with Capital Rx disputing findings.

By Amara Osei

3 min read

Florida OIR Fines PBMs $12.6 Million After Market Conduct Exams
Florida OIR Fines PBMs $12.6 Million After Market Conduct Examsstevepb / pixabay

What's News

  • Florida OIR fined 12 PBMs more than $12 million over the last 12 months.
  • Largest fines: Employee Health Insurance Management $2.4M, Scrip World (CVS Health) $2.2M, Right Rx FL $2.1M, Capital Rx $1.6M.
  • The exams stem from Senate Bill 1550, the Prescription Drug Reform Act, signed in 2023, allowing OIR to examine PBMs every two years.
  • OIR's Aug. 28 report found 19% of reviewed Capital Rx contracts lacked required network adequacy terms.

Florida's insurance regulator has fined 12 pharmacy benefit managers more than $12 million over the last 12 months, after market conduct examinations flagged pricing models, unilateral changes to pharmacy contracts and other alleged statutory violations.

The Office of Insurance Regulation conducted the exams under authority granted by Florida Senate Bill 1550, the Prescription Drug Reform Act, signed into law in 2023. The law lets OIR examine PBMs every two years.

Most of the fined companies have accepted OIR's findings and already taken steps to correct deficiencies, according to the regulator. A few are pushing back.

Which PBMs paid the most?

The four largest fines this year break down as follows, according to OIR:

  • Employee Health Insurance Management, a privately held company: $2.4 million
  • Scrip World, owned by CVS Health Corp.: $2.2 million
  • Right Rx FL, a privately owned firm: $2.1 million
  • Capital Rx Inc.: $1.6 million

Why is Capital Rx fighting the findings?

Capital Rx — now operating as Judi Rx, part of Judi Health and backed by a number of institutional investors — disagreed with almost all of the eight red flags OIR raised in its Aug. 28 market conduct exam report.

Examiners found that in 19% of Capital Rx contracts reviewed, the PBM did not include terms covering network adequacy, as required by Florida statute. The company contested the finding.

"Capital Rx disagreed with all of the instances contained in the finding, stating language or similar language in the contract states, 'Members will have access to the network of retail pharmacies established and maintained by Capital Rx to deliver covered pharmaceuticals to members. Capital Rx will maintain or develop a network in sponsor's service area(s) that meets reasonable access standards,'" the exam report reads.

In OIR's view, that contract language did not satisfy Florida's network adequacy requirements. The dispute sets up a test of how far the state can push contract-level compliance under its new examination authority.

What did the insurance commissioner say?

Florida Insurance Commissioner Michael Yaworsky framed the enforcement push as a matter of transparency and consumer protection.

"We must demand transparency and accountability for all pharmacy benefit managers in Florida to ensure companies cannot hide revenue, retain rebates instead of passing savings to consumers or raise costs for patients who may rely heavily on critical prescriptions," Yaworsky said in a statement.

He didn't mince words about the industry's trade groups either. "I understand that drug-pricing can be complex, but it should never be hidden for PBMs' own financial incentives," Yaworsky said. "I want to be clear to PBMs and the associations they hide behind—the laws of Florida will be adhered to, and you will be held accountable."

Why are PBMs under scrutiny nationwide?

Pharmacists and other critics across the country have decried a lack of transparency and allegedly unfair PBM practices that squeezed pharmacies and pushed prices higher for consumers. Florida's exams are part of that broader reckoning, and other states are moving in parallel — Alabama lawmakers, for instance, have set minimum PBM payments to independent pharmacies.

With OIR now empowered to examine PBMs every two years, the $12.6 million in fines is unlikely to be the last word. Companies operating in Florida — including CVS-owned Scrip World — face a recurring compliance cycle, and holdouts like Capital Rx will test how firmly the state enforces its findings.

Source: insurancejournal.com

Share this article:

More from Amara Osei

Amara Osei

Show full bio

Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.

2,136 articles

Related articles

« Previous articleNext article »